Patent intelligence · US
US 10004785
LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
Patent details — US 10004785
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 26, 2018
- Expiration
- Jun 21, 2038
- Applicant
- REGENERX BIOPHARMACEUTICALS, INC.
- Claims
- 15
- CPC classes
- A61K, A61K38/08, A61K38/2292, A61K47/186
Quick answer
US 10004785 (LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized) is held by REGENERX BIOPHARMACEUTICALS, INC.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERX BIOPHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K38/08, A61K38/2292, A61K47/186, A61K9/0048, A61K9/08
More from REGENERX BIOPHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10004785?
US 10004785 (LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized) is held by REGENERX BIOPHARMACEUTICALS, INC.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10004785?
REGENERX BIOPHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10004785 expire?
Our index shows an expiration date of Jun 21, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.